ADVISORY, Nov. 08, 2017 (GLOBE NEWSWIRE) —
What:
InflaRX NV (Nasdaq:IFRX), a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a, will visit the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO) on November 8, 2017.